Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With

The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with lung cancer and Eligible patients had advanced lung cancer of any histology, no standard treatment options, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and tumors with Twenty-eight patients with lung cancer (27 non-small-cell, 1 small-cell) and Combination P + T showed evidence of antitumor activity in heavily pretreated patients with non-small-cell lung cancer and